Breast Cancer

Signaling through a complex of proteins called mTORC2 plays a role in breast cancer migration, invasion and metastasis, Vanderbilt researchers reported. Read More

Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center in Dallas. Read More

A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer. Read More

Vanderbilt-Ingram Cancer Center (VICC), in collaboration with the Hereditary Cancer Program and the Vanderbilt Breast Center, is hosting a free seminar, “Are You at High Risk for Breast Cancer?” Read More

A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy. Read More

Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer. Read More

DS Services of America Inc. recently presented a $100,000 gift to Vanderbilt-Ingram Cancer Center (VICC) to support breast cancer research. Read More

Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients. Read More

Tumors cause the intracellular material surrounding them to stiffen. Softening this protective layer could make existing cancer treatments more effective, according to new research. Read More

A novel drug that targets the protein RSK blocked aggressive breast cancers from metastasizing in an animal model. Read More

It is important to be aware of resources for those touched by cancer in our workplace. Read More

Know the facts about breast cancer, celebrate survivorship, honor and remember loved ones, and raise awareness about steps to reduce the risk of getting breast cancer--including having an early detection plan. Read More

For breast cancer prevention, a new study provides evidence for lifestyle modification to reduce weight gain in adults. Read More

Lymphedema research conducted at Vanderbilt University Medical Center (VUMC) to better understand patient risk for this chronic condition and treatment responses received recognition at an international conference. Read More

Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers. Read More

Vanderbilt investigators have demonstrated that a certain protein complex drives tumor progression in aggressive breast cancers. Read More

A new method developed at Vanderbilt may help “inventory” all tumor-promoting genes. Read More

A cancer research consortium headed by investigators at Vanderbilt-Ingram Cancer Center and two other institutions have received $12 million in federal funding to help determine why African-American women die at a higher rate and have more aggressive breast cancer than white women. Read More

A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies. Read More

Signaling by a receptor that is overexpressed in aggressive forms of breast cancer has been linked to glutamine metabolism, suggesting new anti-cancer therapeutic targets. Read More